This article is more than 5 years old. Information may no longer be current.
PiXL promising noninvasive treatment of low myopia
Click Here to Manage Email Alerts
Two studies presented at the congress of the European Society of Cataract and Refractive Surgeons showed that nonsurgical photorefractive intrastromal corneal collagen cross-linking, or PiXL, may be a promising new treatment for vision improvement for low myopia, according to a press release from Avedro.
The first study, a prospective clinical trial conducted at Ruhr University Eye Hospital, Bochum, Germany, evaluated the safety and efficacy of epithelium-off PiXL. The 12-month study included 39 eyes in two groups. Month 12 results demonstrate significant improvement with mean uncorrected visual acuity of 20/20 at 12 months and no loss of best-corrected visual acuity. Based on these results, the data demonstrate that PiXL is a promising refractive procedure for low myopia, according to the release.
The second study, performed in Singapore, analyzed the safety and efficacy of transepithelial PiXL in correcting low myopia. Researchers evaluated treatment results in eight patients who underwent the procedure and were followed for 9 months postoperatively. Findings included a mean myopia reduction of 0.75 D at 9 months, according to the release.